Stuart Therapeutics Announces Completion of Phase 3 Dry Eye Disease Clinical Trial
Press Releases
January 21, 2025

Stuart Therapeutics Announces Completion of Phase 3 Dry Eye Disease Clinical Trial

STUART, Fla., Jan. 21, 2025 /PRNewswire/ -- Stuart Therapeutics, Inc. (Stuart), a clinical-stage drug platform company developing novel therapies for ophthalmic diseases, today announced last patient last visit in the

bradford

The Bradford Era

More by this Author
Local & Social